Three dimensional staging of breast cancer

SummaryPurposeBreast cancers are three dimensional solids but very few are spherical. We hypothesized that calculations based on the greatest diameter would not accurately reflect tumor volume and that three dimensional measurements would affect tumor staging.Materials and methods: 165 invasive carcinomas measuring 2.5 cm or less and having three measured diameters (a ≥ b ≥ c) noted were evaluated. Tumor volume was calculated using four geometric models: the spherical 4/3π (a/2)3, prolate spheroid 4/3π (a/2) (c/2)2, oblate spheroid 4/3π (a/2)2 (b/2), and ellipsoid 4/3π (a/2 × b/2 × c/2). The ellipsoid correctly determined the volume for any tumor shape. All cases were stratified according to the TNM staging system. Differences in mean volume calculated as a sphere and ellipsoid for each tumor subclass were analyzed using Student's T test. The reclassification of tumors by the ellipsoid formula was determined.Results: Seventy-six (46.1%) had tumors with three different diameters while only six (3.6%) were true spheres having three identical diameters. Mean tumor volume analysis of T1a, T1b, T1c, and T2 tumors demonstrated a statistically significant overestimation of volume when utilizing the sphere formula instead of the ellipsoid formula (p < 0.05). The differences in volume were more dramatic as the diameters increased. A total of 41 tumors were moved into smaller T subclasses including 10 node positive patients.Conclusions: Tumor volume analysis demonstrates that use of only the greatest diameter poorly reflects the true volume of a lesion and consistently overestimates volume. The ellipsoid formula accurately calculates volume for these three dimensional tumors and when utilized has significant relevance to staging small invasive breast cancers.

[1]  M. Silverstein,et al.  Axillary lymph node dissection for t1a breast carcinoma. Is it indicated? , 1994, Cancer.

[2]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[3]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[4]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[5]  K. Forde,et al.  Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. , 1989, Surgery.

[6]  J. Spratt,et al.  Growth rates of primary breast cancers , 1979, Cancer.

[7]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[8]  Axillary lymph node dissection for t1a breast carcinoma. Is it indicated? , 1994 .

[9]  L. Norton,et al.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Atkinson,et al.  Tumor volume, nodal status, and metastasis in breast cancer in women. , 1986, Journal of the National Cancer Institute.

[11]  L. Norton,et al.  Potential innovations in scheduling of cancer chemotherapy. , 1991, Important advances in oncology.

[12]  J. Seidman,et al.  Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis , 1995, Cancer.

[13]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .